A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Exclusion Criteria

• •Subject is able to continue on the treatment regimen that the subject was receiving in the prior study. If in the investigator's assessment, a change is needed to the subject's regimen (e.g., dose change in Androgen deprivation therapy (ADT) or dropping of a combination therapy) approval from a medical monitor is required prior to enrollment.
• •Subject is able to swallow enzalutamide capsules and comply with study requirements.
• •Subject and female partner who is of childbearing potential must continue to use 2 forms of birth control, of which 1 must be highly effective and 1 must be a barrier method throughout the study and for 3 months after final enzalutamide administration.
• •Subject agrees to avoid sperm donation during the study and for at least 3 months after final enzalutamide administration.
• •Subject agrees not to participate in another interventional study while on treatment.
• •Canada Specific:
• •Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act authorization for the United States sites) must be obtained from the subject prior to any study-related procedures.
• •Subject is able to continue on the treatment regimen that they were receiving in the prior study. If in the investigator's assessment, a change is needed to the subject's regimen (e.g., dropping of a combination therapy) approval from a medical monitor is required prior to enrollment.
• •Subject is able to swallow enzalutamide capsules and comply with study requirements.
• •Subject is either:
• +29 more criteria